Phase II Study of BAY 43-9006 (NSC 724772) [sorafenib] as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma.

Trial Profile

Phase II Study of BAY 43-9006 (NSC 724772) [sorafenib] as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2012 Actual patient number is 36 as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Actual end date (1 Jan 2010) added as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top